Treffer: Comparing machine learning algorithms to predict 5-year survival in patients with chronic myeloid leukemia.
IEEE J Biomed Health Inform. 2022 Apr;26(4):1472-1483. (PMID: 33848254)
Leuk Res. 2018 Dec;75:50-57. (PMID: 30458320)
J Am Med Inform Assoc. 2020 Jul 1;27(7):1019-1027. (PMID: 32483590)
PLoS One. 2021 Jul 21;16(7):e0254976. (PMID: 34288963)
PLoS One. 2020 Dec 31;15(12):e0244869. (PMID: 33382829)
Am J Hematol. 2021 Feb 1;96(2):241-250. (PMID: 33180322)
J Cancer. 2021 Jun 11;12(16):4912-4923. (PMID: 34234861)
Front Oncol. 2021 Mar 29;11:657191. (PMID: 33854980)
J Pers Med. 2021 Jan 07;11(1):. (PMID: 33430240)
Am J Gastroenterol. 2013 Nov;108(11):1723-30. (PMID: 24169273)
Nat Rev Rheumatol. 2019 Jan;15(1):49-60. (PMID: 30523334)
Blood Cancer J. 2019 Sep 30;9(10):75. (PMID: 31570695)
Acta Biomed. 2020 Nov 10;91(4):e2020147. (PMID: 33525218)
BMJ Open. 2021 Nov 2;11(11):e052887. (PMID: 34728455)
Int J Med Inform. 2017 Dec;108:1-8. (PMID: 29132615)
Am J Clin Pathol. 2021 Nov 8;156(6):1142-1148. (PMID: 34184028)
Eur J Cancer. 2008 May;44(8):1146-56. (PMID: 18394880)
Haematologica. 2023 Mar 01;108(3):690-704. (PMID: 35708137)
Neurosurg Focus. 2018 Nov 1;45(5):E2. (PMID: 30453455)
Ann Hematol. 2021 Feb;100(2):481-485. (PMID: 33415425)
Medicine (Baltimore). 2019 Nov;98(48):e18079. (PMID: 31770225)
J Pediatr Hematol Oncol. 2021 Apr 1;43(3):e371-e374. (PMID: 32134839)
J Pain Symptom Manage. 2017 May;53(5):962-970.e10. (PMID: 28062344)
Leukemia. 2019 Jul;33(7):1543-1556. (PMID: 31127148)
Weitere Informationen
Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disorder resulting from the translocation of chromosomes 19 and 22. CML includes 15-20% of all cases of leukemia. Although bone marrow transplant and, more recently, tyrosine kinase inhibitors (TKIs) as a first-line treatment have significantly prolonged survival in CML patients, accurate prediction using available patient-level factors can be challenging. We intended to predict 5-year survival among CML patients via eight machine learning (ML) algorithms and compare their performance.
Methods: The data of 837 CML patients were retrospectively extracted and randomly split into training and test segments (70:30 ratio). The outcome variable was 5-year survival with potential values of alive or deceased. The dataset for the full features and important features selected by minimal redundancy maximal relevance (mRMR) feature selection were fed into eight ML techniques, including eXtreme gradient boosting (XGBoost), multilayer perceptron (MLP), pattern recognition network, k-nearest neighborhood (KNN), probabilistic neural network, support vector machine (SVM) (kernel = linear), SVM (kernel = RBF), and J-48. The scikit-learn library in Python was used to implement the models. Finally, the performance of the developed models was measured using some evaluation criteria with 95% confidence intervals (CI).
Results: Spleen palpable, age, and unexplained hemorrhage were identified as the top three effective features affecting CML 5-year survival. The performance of ML models using the selected-features was superior to that of the full-features dataset. Among the eight ML algorithms, SVM (kernel = RBF) had the best performance in tenfold cross-validation with an accuracy of 85.7%, specificity of 85%, sensitivity of 86%, F-measure of 87%, kappa statistic of 86.1%, and area under the curve (AUC) of 85% for the selected-features. Using the full-features dataset yielded an accuracy of 69.7%, specificity of 69.1%, sensitivity of 71.3%, F-measure of 72%, kappa statistic of 75.2%, and AUC of 70.1%.
Conclusions: Accurate prediction of the survival likelihood of CML patients can inform caregivers to promote patient prognostication and choose the best possible treatment path. While external validation is required, our developed models will offer customized treatment and may guide the prescription of personalized medicine for CML patients.
(© 2022. The Author(s).)